Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional)
National Institutes of Health
Award ceiling
—Award floor
—Posted
Oct 1, 2024Closes
Aug 18, 2027Location eligibility
No specific state restriction found in this listing — check the full opportunity for details.Categories: Education, Environment, Health
Eligible applicants: Private institutions of higher education, Special district governments, Public housing authorities/Indian housing authorities, Small businesses, County governments, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), City or township governments, Others (see text field entitled "Additional Information on Eligibility" for clarification), Independent school districts, For profit organizations other than small businesses, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education, Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education, State governments
Description
The Blueprint Neurotherapeutics Network for Biologics (BPN-Biologics) provides support for biologic-based therapeutic discovery and development, from lead optimization through phase I clinical testing. This Funding Opportunity Announcement (FOA) supports preclinical discovery and development of potential therapeutic Biotechnology Products and Biologics including, but not limited to, large biologic macromolecules, (e.g., proteins, antibodies, and peptides), gene-based therapies (i.e., oligonucleotide- and viral-based), cell therapies, and novel emerging therapies (e.g., microbial and microbiome therapies). Applicants will collaborate with NIH-funded consultants and can augment their project with NIH contract research organizations (CROs) that specialize in manufacturing, scaling, pharmacokinetics, toxicology, and Phase I clinical testing. BPN-Biologics awardee institutions retain their assignment of IP rights and gain assignment of IP rights from the BPN-Biologics contractors (and thereby control the patent prosecution and licensing negotiations) for biotherapeutic candidates developed in this program.